Stock Analiz

Cerenome, Inc. CNSY

Medical/Dental Instruments · data as of November 13, 2026

$0.95Market cap $7M
Open the interactive analysis →

Cerenome, Inc. (CNSY) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$30M, a net margin of -859.5%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -218%.

About Cerenome

Cerenome is listed in the US and classified in medical/dental instruments. Revenue went from $5M in 2014 to $5M in 2025, growth of about 0.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 4345% over three years (dilution for shareholders). It spends 161% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-397.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-10.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-307.8%
ROIC (5-yr avg.)-218.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4M$5M$6M$5M————$4M$3M$5M
Net income-$30M-$22M-$13M-$13M-$20M-$13M-$8M-$11M-$13M-$23M-$22M
Free cash flow-$29M-$21M-$11M-$13M———-$6M-$12M-$18M-$20M
EPS (diluted)$-3.36$-2.90$-23.40$-42.40$-115.80$-166.50$-279.00$-1240.50$-13047.00$-61725.02$-96000.04
Net margin-859.5%-429.4%-222.8%-271.0%————-344.2%-843.7%-473.5%
ROIC—-317.6%—-371.5%-128.8%-55.4%-75.6%-22.2%-35.6%-61.4%-54.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $27.75, 2820% above the current price; targets range from $12.00 to $43.00; the consensus rating is “none”; expected EPS is $-4.43 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Cerenome pay a dividend?

Not currently.

Is Cerenome a good stock to buy?

We do not give buy or sell advice. Cerenome scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.